High-Complexity Testing for Precision Medicine
Actionable Insights for Better Care
We support clinicians with reliable, high-quality diagnostic data to inform treatment strategies and ongoing disease management.
Our testing capabilities are designed to:
– Enable earlier and more accurate detection of disease relapse
– Monitor disease progression and depth of treatment response
– Support personalized therapeutic decision-making
Clearer Insights. Better Disease Management.
We provide advanced, minimally invasive testing that enables more frequent and informative monitoring of disease.
Our approach supports:
– Blood-based monitoring of minimal residual disease (MRD)
– More frequent testing to track disease status over time
– Improved visibility into treatment effectiveness
By delivering precise and consistent results, we help clinicians better guide each patient’s treatment journey and improve overall outcomes.
Enabling Clinical Trials and Translational Research
Corgenix Clinical Laboratory is a trusted partner to pharmaceutical and biotechnology companies, delivering high-quality laboratory solutions that accelerate clinical development and drive regulatory success.
M-inSight® provides a powerful, minimally invasive approach to monitoring treatment response in multiple myeloma. By using peripheral blood instead of bone marrow, M-inSight® enables more consistent sample collection, higher testing success rates, and the ability to longitudinally track both depth and kinetics of response across diverse patient populations—including newly diagnosed, relapsed/refractory, and extramedullary disease.
As the field continues to evolve, minimal residual disease (MRD) has become a critical biomarker for evaluating therapeutic efficacy. In April 2024, the FDA’s Oncologic Drugs Advisory Committee unanimously supported MRD-negative complete response as an early endpoint reasonably likely to predict clinical benefit—reinforcing MRD’s growing role in enabling accelerated approval pathways.
Corgenix supports:
– Clinical trials (Phase I–IV)
– Investigator-initiated studies
With deep expertise in proteomics and mass spectrometry, we deliver robust, reproducible data that empowers confident decision-making, strengthens regulatory submissions, and helps bring innovative therapies to patients faster.
